Company Announcements

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EU (WITHDRAWAL) ACT 2018 ("MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN MAR) WERE TAKEN IN RESPECT OF THE PLACING WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED IN MAR), AS PERMITTED BY MAR. THIS INSIDE INFORMATION IS SET OUT IN THIS ANNOUNCEMENT. THEREFORE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION RELATING TO THE COMPANY AND ITS SECURITIES.

1 May 2026

GenIP Plc

("GenIP" or the "Company")

Share Placing to raise £350,000 and TVR

GenIP Plc (AIM:GNIP), a technology consultancy providing AI-driven services to help research organisations and corporations commercialise their innovations, is pleased to announce a fundraising of £350,000 (c.US$470,000) (gross) through a placing of 5,000,000 new ordinary shares of £0.00425 each in the Company ("Placing Shares") at a price of 7p ("Issue Price") per Placing Share (the "Placing" or "Fundraising").

Key Highlights:

-     £350,000 (US$470,000) before expenses raised pursuant to the Placing of 5,000,000 Placing Shares at a price of 7p per Placing Share.

-     Funds raised will be utilised as follows:

·      £100,000 for staffing, including account management staff to manage the increasing network of partnerships and alliances. 

·      £150,0000 for R&D efforts associated with new product development and platform development; and

·      £100,000 for general working capital purposes, including Fundraising fees.

GenIP continues to deliver positive trading, has strengthened its relationships with academia clients and its recent alliance with Cardinal IP. The Company recently secured a contract with a university in Peru, which means that it now operates across 33% of South American nations. It has also signed a new corporate contract with a healthcare innovation client in Spain increasing its footprint in Europe and providing access to a network of 122 research groups.

Melissa Cruz, GenIP's CEO, commented:

"This Fundraise comes at a time of significant commercial momentum for GenIP. The proceeds will enable us to improve the monetization of the increasing network of partnerships and alliances and continue the programme of product development. This places the Company in a stronger position for a successful rest of FY2026."

Placing

The Company has raised £350,000 (before expenses) through the issue of 5,000,000 Placing Shares at an issue price of 7p per Placing Share, which represents a discount of approximately 38% to the closing mid-price of 11.25p as at the close of business on 30 April 2026, being the last practicable date prior to publication of this announcement. The Placing Shares represent approximately 24.4% of the Company's existing issued share capital. The Placing was undertaken by CMC Markets UK Plc ("CMC"), trading as CapX, who acted as the Company's sole placing agent in respect of the Placing.

The net proceeds of the Placing will support GenIP's growth plans, will strengthen the Company's balance sheet and provide additional working capital.

Appointment of Joint Broker

The Company is also pleased to announce that CMC has been appointed as the Company's joint corporate broker with immediate effect.

Application for Admission

Application will be made for the Placing Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will take place and that trading will commence on AIM at 8.00 a.m. on or around 8 May 2026. Once issued, the Placing Shares will rank pari passu with the Company's existing Ordinary Shares.

Total Voting Rights

Following Admission of the Placing Shares, the enlarged issued share capital of the Company will comprise 25,517,461 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Consequently, 25,517,461 is the figure which may be used by shareholders from Admission as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Concert Party interest

The Concert Party (as defined in the Admission Document published on 26 September 2024), is currently interested in aggregate in 60.88% of the existing issued share capital reducing to 48.95% in the enlarged issued share capital on Admission. Accordingly, following Admission the members of the Concert Party will hold less than 50 per cent. of the voting rights in the Company but will continue to hold more than 30 per cent. of the voting rights of the Company.  If a Concert Party member is in any doubt about the current position, it should consult the Company and seek their own financial advice from an appropriately authorised stockbroker, bank manager, solicitor, accountant or other independent financial adviser who, if taking advice in the United Kingdom, is duly authorised under the Financial Services and Markets Act 2000 ("FSMA").

ENDS

For further information regarding GenIP, please visit www.genip.ai, or contact:

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

Notes to Editors

About GenIP

GenIP is a next-generation company at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.

Service Offerings

GenIP operates through two synergistic service lines:

Together, these services form a unified GenAI-enabled platform for innovation triage and commercialisation.

Vision & Strategy

GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:

●     Organic Expansion
Scale Invention Intelligence and Recruitment Services through targeted outreach to corporates, VCs, and research institutions.

●     Service Deepening
Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.

●     Strategic Acquisitions
Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.

Forward looking statements

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.